Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 19/20 | 0.73 |
| ▸ | FLT3 | P36888 | 4/20 | 0.73 |
| ▸ | BLK | P51451 | 2/20 | 0.73 |
| ▸ | BTK | Q06187 | 3/20 | 0.61 |
| ▸ | JAK3 | P52333 | 1/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30353469 | 0.92 | EGFR (0.87) | EGFRFLT3BLKBTKJAK3 | |
| SCHEMBL18294430 | 0.92 | EGFR (0.87) | EGFRFLT3BLKBTKJAK3 | |
| SCHEMBL20080150 | 0.91 | EGFR (0.68) | EGFRFLT3BLKBTKJAK3 | |
| SCHEMBL30353479 | 0.91 | EGFR (0.69) | EGFRFLT3BLKBTKJAK3 | |
| SCHEMBL29572794 | 0.91 | EGFR (0.69) | EGFRFLT3BLKBTKJAK3 | |
| SCHEMBL18294533 | 0.91 | EGFR (0.69) | EGFRFLT3BLKBTKJAK3 | |
| SCHEMBL30353476 | 0.88 | FLT3 (0.71) | EGFRFLT3BLKBTKJAK3 | |
| SCHEMBL18294536 | 0.88 | FLT3 (0.71) | EGFRFLT3BLKBTKJAK3 | |
| SCHEMBL18294440 | 0.86 | EGFR (0.86) | EGFRFLT3BLKBTKJAK3 | |
| SCHEMBL30353468 | 0.86 | EGFR (0.86) | EGFRFLT3BLKBTKJAK3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180148454-A1 | USE OF PTERIDINONE DERIVATIVE SERVING AS EGFR INHIBITOR | Shanghai Yidian Pharmaceutical Technology Development Co., Ltd. (CN) | 2018-05-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180148454-A1 | USE OF PTERIDINONE DERIVATIVE SERVING AS EGFR INHIBITOR | EGFR, ERBB2, ERBB3 | EGFR 1/4885FLT3 20/4885BLK 515/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.